The SNS Densomere™ Platform for Controlled/Extended Drug Delivery

Benefits

  • Sustains and controls drug release and bioactivity of small and large molecules over extended periods following a single administration
  • Requires only the API and polymer
  • Can deliver a large variety of drugs, including monoclonal antibodies, for multiple disease states with minimal untoward response
  • Regulates drug release with resorbable microparticle carriers
  • Regulates delivery volume/drug loading
  • Regulates particle size and therefore needle gauge
  • Causes intravitreal microparticles to descend to inferior periphery (leaving visual axis undisturbed — no snow globe)
  • Requires only API and polymer
  • Reduces inflammatory response & oxygen degradation of APIs

SNS technology shows one year In-Vivo bioactivity of macromolecules following a single administration.

Using a rabbit model, studies utilizing a corneal model indicate one year bioactivity in preventing angiogenesis with Avastin, and similar in-vitro results in other macromolecules.

SNS Inhibition of Neovascularization

52 weeks post single subconjunctival injection
Rabbit corneal model with continuous resuturing

Multiple Routes of Drug Delivery

Implantation

Injection

Inhalation

Transdermal

Patient self-administration

SNS Can Engineer Particle Size

To inject microparticles, the largest particles must be < 1/3 of the inner diameter of the needle

E.g., to inject with a 27-gauge needle (inner diameter is 267 µm) particle size must be < 90 µm

SNS Densomeres can be engineered from nano to micro sizes

Short-term Drug Delivery

  • 20 days in vitro release study
  • Model drug: Dexamethasone
  • Consistent effects of 1 densification level with 3 trials

165 days in Vitro Release Study

  • 20 days in vitro release study
  • Model drug: Dexamethasone
  • Varying release rates following three different Densomere levels